•  

University of Toronto

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor Toronto, December 6, 2011 —  The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research. The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…) Read more

Xagenic secures $1 million investment from Ministry of Research & Innovation

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in funding by Ontario’s Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund‐Life Sciences (IAF-­LS) program. Research and Innovation Minister Glen Murray made the announcement at MaRS Discovery District. “Today’s announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing — instead ... Read more

OtoSim Inc. launches revolutionary simulator-training system to improve otoscopic diagnostic efficiency

MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to commercialize an otoscopy training system and process developed by two otolaryngologists at SickKids. The new product, the OtoSim™ program and training device, is the first in a series of training systems directed at improving the accuracy of ear examinations. Using simulation-based training is part of a wider trend in medicine. In otoscopy, healthcare professionals ... Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc. When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million. This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ... Read more

MaRS Innovation selects University of Toronto’s Diabetic Wound Healing Technology as second commercialization opportunity

TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. “There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ... Read more
Page 17 of 17« First...10...1314151617